Researchers now have access to a powerful new genomic sequencing tool through the Indiana University School of Medicine’s Center for Medical Genomics, a state-of-the-art technology core located in Indianapolis that provides medical scientists with affordable access to high-quality, high-throughput genomics services.
The center, which has a fee-for-service model, recently acquired the Illumina NovaSeq X Plus—an instrument that exponentially expands the possibilities of how far next-generation sequencing can go. It launched the NovaSeq X Plus on Aug. 16 with an educational seminar and will offer NovaSeq X Plus sequencing services starting Friday, Sept. 1.
This acquisition makes IU School of Medicine one of the only academic institutions in the Midwest with a NovaSeq X Plus for research use.
The NovaSeq X Plus offers Illumina’s most advanced, powerful sequencing to date, delivering an unprecedented combination of high throughput and accuracy. It also features streamlined informatics, breakthrough sustainability advancements and cost-effective sequencing economics.
Yunlong Liu, PhD, MS, director of the Center for Medical Genomics and T.K. Li Professor of Medical Research at IU School of Medicine, said the addition of this high-performance instrument will lower the cost per gigabase (Gb) by up to 60% compared to the NovaSeq 6000 system.
“I am confident that the significant cost savings provided by using the NovaSeq X Plus will allow researchers to increase the statistical power of their study by sequencing more samples,” Liu said.
The center is also equipped with a variety of advanced genomics technologies and Illumina sequencers, including NovaSeq 6000, NextSeq 2000 and MiSeq Dx. In 2022, it sequenced 13,700 samples for 184 researchers from Indiana University, Purdue University, the University of Notre Dame, Eli Lilly, Ohio State University, the University of Kentucky, and the University of Nebraska.
The $1.25 million instrument was purchased with support from the IU School of Medicine Dean’s Office, the IU Melvin and Bren Simon Comprehensive Cancer Center, and many other IU research centers and basic science and clinical departments.
To learn more about the NovaSeq X Plus, contact email@example.com.
The views expressed in this content represent the perspective and opinions of the author and may or may not represent the position of Indiana University School of Medicine.